Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-04-20
2002-02-26
Wang, Andrew (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S325000, C536S023100, C536S024500
Reexamination Certificate
active
06350868
ABSTRACT:
FIELD OF THE INVENTION
The present invention concerns oligonucleotides, including antisense oligonucleotides, that are useful in the treatment of cancer, along with DNA encoding the same, vectors that contain such DNA, cells that express such DNA, pharmaceutical formulations containing the same, and methods of use thereof in the treatment of cancer.
BACKGROUND OF THE INVENTION
Antisense oligonucleotides (along with other oligonucleotides that downregulate gene expression) offer the possibility of targeting a specific gene to study its function, inhibit its product, or repair a defect (A. Gewirtz et al.,
Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
Proc. Natl. Acad. Sci. USA, 93: 3161-3163, 1996; L. Long et al.,
Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin
-
like growth factor receptor.
Cancer Res., 55: 1006-1009, 1995; H. Sierakowska et al.,
Repair of thalassemic human
&bgr;-
globin mRNA in mammalian cells by antisense oligonucleotides.
Proc. Natl. Acad. Sci. USA, 93: 12840-12844, 1996). Antisense is therefore an appealing therapeutic strategy for malignancies, as it avoids some of the widely cytotoxic effects of current cancer therapy (J. Cheng et al.,
Amplification of AKT
2
in human pancreatic cancer cells and inhibition of AKT
2
expression and tumorigenicity by antisense RNA.
Proc. Natl. Acad. Sci. USA, 93: 3636-3641, 1996). Clinically, antisense offers an advantage over antibody-based targeting (T. Kishimoto et al.,
Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of sialyl Lewis a antigen.
Int. J. Cancer, 69: 290-294, 1996) because the constructs are often less immunogenic and have more favorable pharmacokinetics (J. Phillips et al.,
Pharmacokinetics, metabolism, and elimination of a
20-
mer phosphorothioate oligodeoxynucleotide
(
CGP
69846
A
)
after intravenous and subcutaneous administration.
Biochem. Pharmacol., 54: 657-668, 1997). Accordingly, there is a continued need for new oligonucleotides that have anticancer activity.
SUMMARY OF THE INVENTION
A first aspect of the present invention is an oligonucleotide that hybridizes to a nucleic acid that encodes a fucosyltransferase (FUT). The fucosyltransferase is preferably FUT3 or FUT6.
A second aspect of the present invention is a pharmaceutical formulation comprising an oligonucleotide as described above in a pharmaceutically acceptable carrier. The oligonucleotide is included in an amount effective to treat a cancer as described herein, typically from about 0.01 percent to about 99 percent by weight of the formulation.
A third aspect of the present invention is a method of treating a subject afflicted with cancer (e.g., a carcinoma), comprising administering to the subject an oligonucleotide as described above in an amount effective to treat said cancer.
A fourth aspect of the present invention is a nucleic acid encoding an oligonucleotide that hybridizes to a nucleic acid that encodes a fucosyltransferase. The fucosyltransferase is preferably FUT3 or FUT6.
A fifth aspect of the present invention is a vector that contains and expresses a nucleic acid as described above.
A sixth aspect of the present invention is a pharmaceutical formulation comprising a vector as described above in a pharmaceutically acceptable carrier. The vector is included in an amount effective to treat cancer, typically from about 0.01 percent to about 99 percent by weight of the formulation.
A seventh aspect of the present invention is a method of treating a subject afflicted with cancer (e.g., a carcinoma), comprising administering to said subject a vector as described above in an amount effective to treat said cancer.
An eighth aspect of the present invention is a cell that contains and expresses a nucleic acid as described above.
The foregoing and other objects and aspects of the present invention are described in the figures herein and the specification set forth below.
REFERENCES:
patent: 5324663 (1994-06-01), Lowe
patent: 5770420 (1998-06-01), Lowe et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5827817 (1998-10-01), Larsen et al.
Branch, A good antisense molecule is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.*
Agrawal, Antisense oligonucleotides:towards clinical trials, TIBTECH, vol. 14, pp. 376-387, Oct. 1996.*
Gewirtz et al., Facilitating oligonucleotide delivery: helping antisense deliver on its promise, PNAS, vol. 93, pp. 3161-3163, Apr. 1996.*
Weston et al., Molecular cloning of a fourth member of a human alpha(1, 3)fucosyltransferase gene family, J. Biol. Chem., vol. 267 (34), pp. 24575-24584, Dec. 5, 1992.*
James, W., Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes,Antiviral Chemistry & Chemotherapy, vol. 2, No. 4, pp. 191-214 (1991).
Milner, Natalie, et al., Selecting effective antisense reagents on combinatorial oligonucleotide arrays,Nature Biotechnology, vol. 15, pp. 537-541 (Jun. 1997).
International Search Report PCT/US00/10547; dated Oct. 4, 2000.
Weston et al.; Molecular Cloning of a Fourth Member of a Human &agr;(1,3)Fucosyltransferase Gene Family,The Journal of Biological Chemistry267:34 24575-24584 (1992).
McCurley et al.; Physical Maps of Human &agr;(1,3)Fucosyltransferase Genes FUT3-FUT6 on Chromosomes 19p13.3 and 11q21,Genomics26 142-146 (1995).
Cameron et al.; Expression of Human Chromosome 19p &agr;(1,3)-Fucosyltransferase Genes in Normal Tissues,The Journal of Biological Chemistry270:34 20112-20122 (1995).
Hiller Kara M.
Weston Brent W.
Myers Bigel Sibley & Sajovec P.A.
University of North Carolina at Chapel Hill
Wang Andrew
LandOfFree
Antisense human fucosyltransferase sequences and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense human fucosyltransferase sequences and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense human fucosyltransferase sequences and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2983938